Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study
Autor: | Naoki Yamamoto, Sayuri Ishiwata, Makoto Tomita, Toru Nishikawa, Kenji Narushima, Masahito Nakataki, Yasuyoshi Ishiwata, Kosaku Shoda, Akeo Kurumaji, Mai Tamaru, Akihito Uezato, Masato Yasuhara, Kunimasa Arima, Kazunari Oshima, Michio Itasaka, Tetsuro Ohmori, Kazuo Takiguchi, Mitsutoshi Okazaki, Hidenori Atsuta |
---|---|
Rok vydání: | 2017 |
Předmět: |
Adult
Male medicine.medical_specialty External capsule lcsh:RC435-571 D-cycloserine Randomized Splenium Corpus callosum White matter 03 medical and health sciences 0302 clinical medicine Double-Blind Method lcsh:Psychiatry Internal medicine medicine Humans Cingulum (brain) Age of Onset Psychiatry Scale for the Assessment of Negative Symptoms MR diffusion tensor imaging Cross-Over Studies Positive and Negative Syndrome Scale Double-blind Glycine Agents Middle Aged Placebo-controlled medicine.disease White Matter 030227 psychiatry Psychiatry and Mental health Diffusion Tensor Imaging medicine.anatomical_structure Cycloserine Schizophrenia Crossover Drug Therapy Combination Female Schizophrenic Psychology Glutamate Psychology 030217 neurology & neurosurgery Antipsychotic Agents Research Article |
Zdroj: | BMC Psychiatry BMC Psychiatry, Vol 17, Iss 1, Pp 1-15 (2017) |
ISSN: | 1471-244X |
Popis: | Background It has been reported that drugs which promote the N-Methyl-D-aspartate-type glutamate receptor function by stimulating the glycine modulatory site in the receptor improve negative symptoms and cognitive dysfunction in schizophrenia patients being treated with antipsychotic drugs. Methods We performed a placebo-controlled double-blind crossover study involving 41 schizophrenia patients in which D-cycloserine 50 mg/day was added-on, and the influence of the onset age and association with white matter integrity on MR diffusion tensor imaging were investigated for the first time. The patients were evaluated using the Positive and Negative Syndrome Scale (PANSS), Scale for the Assessment of Negative Symptoms (SANS), Brief Assessment of Cognition in Schizophrenia (BACS), and other scales. Results D-cycloserine did not improve positive or negative symptoms or cognitive dysfunction in schizophrenia. The investigation in consideration of the onset age suggests that D-cycloserine may aggravate negative symptoms of early-onset schizophrenia. The better treatment effect of D-cycloserine on BACS was observed when the white matter integrity of the sagittal stratum/ cingulum/fornix stria terminalis/genu of corpus callosum/external capsule was higher, and the better treatment effect on PANSS general psychopathology (PANSS-G) was observed when the white matter integrity of the splenium of corpus callosum was higher. In contrast, the better treatment effect of D-cycloserine on PANSS-G and SANS-IV were observed when the white matter integrity of the posterior thalamic radiation (left) was lower. Conclusion It was suggested that response to D-cycloserine is influenced by the onset age and white matter integrity. Trial registration UMIN Clinical Trials Registry (number UMIN000000468 ). Registered 18 August 2006 |
Databáze: | OpenAIRE |
Externí odkaz: |